Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Expert Review of Hematology

• Publication date

  2010-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/ehm.10.22PMID 21082977PMCID PMC3793890
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adherence to hydroxyurea therapy in children with sickle cell anemia.

  2010cited by this paper
• Examining the Effectiveness of Hydroxyurea in People with Sickle Cell Disease

  2010cited by this paper
• Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events

  2009cited by this paper
• A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease.

  2009cited by this paper
• Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilization

  2009cited by this paper
• Racial and ethnic disparities in indicators of a primary care medical home for children.

  2009cited by this paper
• Precaution, cyclooxygenase inhibition, and cardiovascular risk.

  2009cited by this paper
• Definitions of the phenotypic manifestations of sickle cell disease

  2009cited by this paper
• Risk factors for hospital readmission within 30 days: A new quality measure for children with sickle cell disease

  2009cited by this paper
• Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia.

  2009cited by this paper
• The number of people with sickle‐cell disease in the United States: national and state estimates

  2009cited by this paper
• Healthcare utilization and expenditures for low income children with sickle cell disease

  2009cited by this paper
• Racial and ethnic disparities in pain: causes and consequences of unequal care.

  2009cited by this paper
• Hydroxyurea for children with sickle cell disease.

  2008cited by this paper
• Disparity in depression treatment among racial and ethnic minority populations in the United States.

  2008cited by this paper
• Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology.

  2008cited by this paper
• Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.

  2008cited by this paper
• National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.

  2008cited by this paper
• Daily Assessment of Pain in Adults with Sickle Cell Disease

  2008cited by this paper
• Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males

  2008cited by this paper
• Efficacy of Hydroxyurea To Prevent Organ Damage in Young Children with Sickle Cell Anemia.

  2007cited by this paper
• Therapy preference and decision‐making among patients with severe sickle cell anemia and their families &

  2007cited by this paper
• Hospitalization rates and costs of care of patients with sickle‐cell anemia in the state of Maryland in the era of hydroxyurea

  2006cited by this paper
• Hydroxyurea and sickle cell anemia: effect on quality of life

  2006cited by this paper
• Cyclooxygenase inhibition and cardiovascular risk.

  2005cited by this paper
• Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance

  2005cited by this paper
• Variation in hospitalizations and hospital length of stay in children with vaso‐occlusive crises in sickle cell disease

  2005cited by this paper
• Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.

  2005cited by this paper
• Hydroxyurea therapy for sickle cell disease in community‐based practices: A survey of Florida and North Carolina hematologists/oncologists

  2005cited by this paper
• Health‐related quality of life in children with sickle cell disease: child and parent perception

  2005cited by this paper
• Bone marrow transplantation for sickle cell anemia: Progress and prospects

  2005cited by this paper
• Hematology: Basic Principles and Practice, 4th edition

  2005cited by this paper
• Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

  2004cited by this paper
• Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

  2003cited by this paper
• Pain at home in sickle cell disease: an underrecognized problem.

  2002cited by this paper
• Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.

  2002cited by this paper
• Home Management of Pain in Sickle Cell Disease: A Daily Diary Study in Children and Adolescents

  2002cited by this paper
• A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.

  2001cited by this paper
• Five years of experience with hydroxyurea in children and young adults with sickle cell disease.

  2001cited by this paper
• The Social and Cultural Context of Coping with Sickle Cell Disease: III. Stress, Coping Tasks, Family Functioning, and Children’s Adjustment

  1999cited by this paper
• Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

  1999cited by this paper
• Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.

  1996cited by this paper
• Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial.

  1996cited by this paper
• Hydroxyurea therapy in children severely affected with sickle cell disease.

  1996cited by this paper
• Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

  1995cited by this paper
• Effect of age on testicular function in adult males with sickle cell anemia.

  1995cited by this paper
• Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea.

  1995cited by this paper
• Mortality in sickle cell disease. Life expectancy and risk factors for early death.

  1994cited by this paper
• Managing Sickle Cell Disease in Low-Income Families

  1994cited by this paper
• Mortality in sickle cell disease.

  1994cited by this paper
• Pain in sickle cell disease. Rates and risk factors.

  1991cited by this paper
• Pain in children and adolescents with sickle cell disease: a descriptive study.

  1990cited by this paper
• Fertility studies in sickle cell disease: semen analysis in adult male patients.

  1988cited by this paper
• Fertility in males with sickle cell disease.

  1981cited by this paper
• Management of sickle-cell disease

  1974cited by this paper
• THE ANONYMOUS WHITE TABLET.

  1965cited by this paper

• “Does the dose of hydroxyurea correlate with shorter hospital stay and higher fetal hemoglobin levels in patients with sickle cell disease?”

  2026cites this paper
• Factors Associated with Healthcare Utilization in Children with Sickle Cell Disease in Saudi Arabia

  2026cites this paper
• Health-related quality of life and adherence to hydroxyurea in patients with sickle cell anemia in Saudi Arabia

  2026cites this paper
• Design and Refinement of CyberCellTM, a Virtual Reality Health Education Program for Adolescents and Young Adults with Sickle Cell Disease.

  2025cites this paper
• Clinical consultation: The pharmacist's role in hydroxyurea management for sickle cell disease.

  2025cites this paper
• Economic burden of sickle cell disease in the United States: a retrospective analysis of a commercial insurance database

  2025cites this paper
• Hydroxyurea therapy in sickle cell disease: knowledge and prescription patterns among care providers in a low-and middle-income setting

  2025cites this paper
• Economic Burden of Sickle Cell Disease: A Retrospective Study of Pediatric and Adult Individuals With Medicaid Coverage From 2016 to 2020

  2025cites this paper
• Clinical Complications, Mortality, and Healthcare Resource Utilization of Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Ontario, Canada: A Retrospective Cohort Study

  2025cites this paper
• Disease‐modifying therapies for sickle cell disease: Decisional needs and supports among adolescents and young adults

  2024cites this paper
• Prescribing Hydroxyurea in Sickle Cell Disease Patients: The Pattern and Association with Co-Prescribed Medications Used to Manage the Disease Complications

  2024cites this paper
• Adherence outcomes of a liquid hydroxyurea delivery program in a pediatric population

  2024cites this paper
• Hydroxyurea mobile directly observed therapy versus standard monitoring in patients with sickle cell anemia: a phase 2 randomized trial

  2024cites this paper
• Utilization and Perceptions of Hydroxyurea Therapy Among Adult Patients With Sickle Cell Disease in Al Ahsa, Saudi Arabia: A Cross-Sectional Study

  2024cites this paper
• The enigma of sickle cell hepatopathy: Pathophysiology, clinical manifestations and therapy

  2024cites this paper
• Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study

  2024cites this paper
• Endari treatment ameliorates sickle cell-related disruption in intestinal barrier functions and is associated with prolonged survival in sickle cell mice

  2024cites this paper
• Bidirectional processes linking social determinants of health and pediatric sickle cell anemia management: A qualitative study

  2023cites this paper
• Differential sensitivity to hypoxia enables shape‐based classification of sickle cell disease and trait blood samples at point of care

  2023cites this paper
• Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease

  2023cites this paper
• Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease

  2023cites this paper
• The evolving treatment landscape for children with sickle cell disease.

  2023cites this paper
• Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators

  2023cites this paper
• Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease

  2023cites this paper
• A feasibility randomized controlled trial of an mHealth app vs booklets for patient-facing guidelines in adults with SCD

  2023cites this paper
• Global burden of transfusion in sickle cell disease.

  2023cites this paper
• Psychiatric comorbidities in adults with sickle cell disease: A narrative review

  2023cites this paper
• Age-related differences in risks and outcomes of 30-day readmission in adults with sickle cell disease

  2023cites this paper
• Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.

  2023cites this paper
• Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease

  2023cites this paper
• Psychologists as leaders in equitable science: Applications of antiracism and community participatory strategies in a pediatric behavioral medicine clinical trial.

  2023cites this paper
• Efficacy and safety of pharmacological interventions for managing sickle cell disease complications in children and adolescents: Systematic review with network meta‐analysis

  2023cites this paper
• Expecting more: the case for incorporating fertility services into comprehensive sickle cell disease care.

  2023cites this paper
• Outcome of Hydroxyurea Use in SCD and Evaluation of Patients’ Perception and Experience in Nigeria

  2022cites this paper
• Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease

  2022cites this paper
• Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond

  2022cites this paper
• Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease

  2022cites this paper
• Treatment patterns and burden of complications associated with sickle cell disease: A US retrospective claims analysis

  2022cites this paper
• Surveillance for Sickle Cell Disease — Sickle Cell Data Collection Program, Two States, 2004–2018

  2022cites this paper
• Clinico-Demographic characteristics, morbidity and mortality patterns of sickle cell disease in a tertiary institution

  2022cites this paper
• Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities

  2022cites this paper
• Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease

  2022cites this paper
• Treatment of sickle cell disease: Beyond hydroxyurea

  2022cites this paper
• Awareness and Use of the Sickle Cell Disease Toolbox by Primary Care Providers in North Carolina

  2021cites this paper
• Hydroxyurea treatment of sickle cell disease: towards a personalized model-based approach

  2021cites this paper
• Nephrotic syndrome on sickle cell disease: the impact of Hydroxyurea

  2021cites this paper
• Adherence to hydroxyurea, health-related quality of life domains and attitudes towards a smartphone app among Irish adolescents and young adults with sickle cell disease

  2021cites this paper
• Kneeling Was the First Step for Sickle Cell Disease

  2021cites this paper
• Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor

  2021cites this paper
• Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium

  2021cites this paper
• Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA

  2021cites this paper
• Knowledge of fertility and perception of fertility treatment among adults with sickle cell disease (KNOW FERTILITY)

  2021cites this paper
• A call to start hydroxyurea by 6 months of age and before the advent of sickle cell disease complications

  2021cites this paper
• Barriers and Facilitators of Use of Hydroxyurea among Children with Sickle Cell Disease: Experiences of Stakeholders in Tanzania

  2021cites this paper
• Hematopoietic cell transplantation for sickle cell disease: updates and future directions.

  2021cites this paper
• Hematopoietic cell trans plan ta tion for sickle cell dis ease: updates and future direc tions

  2021influential citation
• Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study

  2021cites this paper
• Patient‐focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease

  2021cites this paper
• Crisis in Sickle Cell Disease: Review Article

  2021cites this paper
• Patient Reported Outcomes in Sickle Cell Disease Examined Within a Conceptual Model

  2021cites this paper
• Health Care Disparities Among Adolescents and Adults With Sickle Cell Disease: A Community-Based Needs Assessment to Inform Intervention Strategies

  2020cites this paper
• Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathies

  2020cites this paper
• Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY)

  2020cites this paper
• An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling

  2020cites this paper
• Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study.

  2020cites this paper
• Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic

  2020cites this paper
• The Role of Hematopoietic Stem Cell Transplantation in the treatment of Sickle Cell Disease

  2020cites this paper
• Association between hospital admissions and healthcare provider communication for individuals with sickle cell disease

  2020cites this paper
• A Systematic Review of Medication Adherence Interventions in Pediatric Sickle Cell Disease.

  2020cites this paper
• Voxelotor: novel drug for sickle cell disease

  2020cites this paper
• L-glutamine for sickle cell disease: Knight or pawn?

  2020cites this paper
• Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use

  2020influential citation
• Antisickling Effects of Quercetin may be Associated with Modulation of Deoxyhaemoglobin, 2, 3-bisphosphoglycerate mutase, Redox Homeostasis and Alteration of Functional Chemistry in Human Sickle Erythrocytes.

  2019cites this paper
• Reducing Health Care Disparities in Sickle Cell Disease: A Review

  2019cites this paper
• Barriers that prevent initial prescription of hydroxyurea in sickle cell disease

  2019cites this paper
• Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date

  2019cites this paper
• The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease

  2019cites this paper
• Shared Care for Adults with Sickle Cell Disease: An Analysis of Care from Eight Health Systems

  2019cites this paper
• Hydroxyurea: Pattern of Use, Patient Adherence, and Safety Profile in Patients with Sickle Cell Disease in Oman

  2019cites this paper
• Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children

  2019cites this paper
• Patterns of prescribing hydroxyurea for sickle cell disease patients from a central hospital, Saudi Arabia

  2019cites this paper
• Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease

  2019cites this paper
• “Maximum tolerated dose” vs “fixed low‐dose” hydroxyurea for treatment of adults with sickle cell anemia

  2019cites this paper
• A multi‐institutional comparison of younger and older adults with sickle cell disease

  2019cites this paper
• Current Non-HSCT Treatments for SCD

  2018cites this paper
• Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea

  2018cites this paper
• Treatment Options for Sickle Cell Disease.

  2018cites this paper
• Sickle Cell Disease: Advances in Treatment

  2018cites this paper
• Quality of Life, Clinical Effectiveness, and Satisfaction in Pediatric and Young Adult Patients with Sickle Cell Disease Receiving Hydroxyurea Therapy

  2018cites this paper
• Technology use and preferences to support clinical practice guideline awareness and adherence in individuals with sickle cell disease

  2018cites this paper
• Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis

  2018cites this paper
• Adaptation of a microbead assay for the easy evaluation of traditional anti-sickling medicines: application to DREPANOSTAT and FACA

  2018cites this paper
• Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease

  2018cites this paper
• Effect of Hydroxyurea Therapy on Pulmonary Function in Children with Sickle Cell Anemia.

  2017cites this paper
• Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults

  2017cites this paper
• Crizanlizumab in Sickle Cell Disease.

  2017cites this paper
• Increased risk of leukemia among sickle cell disease patients in California.

  2017cites this paper
• Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania

  2016cites this paper
• GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half‐life in a murine model of sickle cell disease

  2016cites this paper
• Translating sickle cell guidelines into practice for primary care providers with Project ECHO

  2016cites this paper